SGCG and pancreatic neoplasm: Vactosertib (EW-7197), a type I TGF-β receptor inhibitor, has been shown to augment gemcitabine and decrease the expression of ECM components, improving the sensitivity of pancreatic cancer cells to gemcitabine (Figure 1B) (106).